NZ591142A - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide - Google Patents
Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideInfo
- Publication number
- NZ591142A NZ591142A NZ591142A NZ59114206A NZ591142A NZ 591142 A NZ591142 A NZ 591142A NZ 591142 A NZ591142 A NZ 591142A NZ 59114206 A NZ59114206 A NZ 59114206A NZ 591142 A NZ591142 A NZ 591142A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- salts
- ylamino
- imidazol
- pyrimidin
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical class C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 229940077388 benzenesulfonate Drugs 0.000 abstract 1
- 239000001177 diphosphate Substances 0.000 abstract 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70140605P | 2005-07-20 | 2005-07-20 | |
US71621305P | 2005-09-12 | 2005-09-12 | |
NZ564182A NZ564182A (en) | 2005-07-20 | 2006-07-18 | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ591142A true NZ591142A (en) | 2012-09-28 |
Family
ID=37398525
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ591142A NZ591142A (en) | 2005-07-20 | 2006-07-18 | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
NZ564182A NZ564182A (en) | 2005-07-20 | 2006-07-18 | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ564182A NZ564182A (en) | 2005-07-20 | 2006-07-18 | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Country Status (34)
Country | Link |
---|---|
US (4) | US8163904B2 (en) |
EP (2) | EP1910336B1 (en) |
JP (1) | JP5129132B2 (en) |
KR (3) | KR20080027855A (en) |
CN (1) | CN102267981A (en) |
AR (1) | AR057467A1 (en) |
AT (1) | ATE514689T1 (en) |
AU (2) | AU2006276205C1 (en) |
BR (1) | BRPI0613605A2 (en) |
CA (2) | CA2823946C (en) |
CY (1) | CY1111772T1 (en) |
DK (1) | DK1910336T3 (en) |
EC (1) | ECSP088118A (en) |
ES (1) | ES2634291T3 (en) |
GT (1) | GT200600316A (en) |
HK (1) | HK1116778A1 (en) |
HR (1) | HRP20110639T1 (en) |
IL (1) | IL187787A (en) |
JO (1) | JO2757B1 (en) |
MA (1) | MA29686B1 (en) |
MX (1) | MX2008000892A (en) |
MY (1) | MY149889A (en) |
NO (1) | NO341313B1 (en) |
NZ (2) | NZ591142A (en) |
PE (1) | PE20070241A1 (en) |
PL (1) | PL1910336T3 (en) |
PT (1) | PT1910336E (en) |
RU (4) | RU2483065C2 (en) |
SG (1) | SG170772A1 (en) |
SI (1) | SI1910336T1 (en) |
TN (1) | TNSN08028A1 (en) |
TW (1) | TWI455934B (en) |
UY (1) | UY29683A1 (en) |
WO (1) | WO2007015871A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200600315A (en) * | 2005-07-20 | 2007-03-19 | CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA | |
GT200600316A (en) | 2005-07-20 | 2007-04-02 | SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA. | |
CA2644841C (en) * | 2006-04-07 | 2013-07-16 | Novartis Ag | Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
US20100016590A1 (en) | 2008-07-17 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Nilotinib intermediates and preparation thereof |
CN102203084B (en) | 2008-11-05 | 2014-10-29 | 特瓦制药工业有限公司 | Nilotinib hci crystalline forms |
EP2186514B1 (en) * | 2008-11-14 | 2016-06-29 | Kinki University | Treatment of Malignant Peripheral Nerve Sheath Tumors |
BRPI1013366A2 (en) | 2009-03-06 | 2016-03-29 | Novartis Ag | use of pyrimidylaminobenzamide derivatives for the treatment of leucine zipper containing kinase and sterile alpha motif (zak) kinase mediated disorders. |
TW201102068A (en) | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
WO2011033307A1 (en) | 2009-09-17 | 2011-03-24 | Generics [Uk] Limited | Nilotinib dihydrochloride salt |
US20120202836A1 (en) | 2009-10-23 | 2012-08-09 | Tomasz Szczudlo | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
JO3634B1 (en) | 2009-11-17 | 2020-08-27 | Novartis Ag | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
IN2010KO00035A (en) | 2010-01-15 | 2016-09-02 | ||
JP2013525296A (en) | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | Treatment of endocrine therapy-resistant breast cancer |
EP2382976A1 (en) | 2010-04-30 | 2011-11-02 | Hiroshima University | Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer |
CA2803559A1 (en) | 2010-06-21 | 2011-12-29 | Teva Pharmaceutical Industries Ltd. | Nilotinib salts and crystalline forms thereof |
WO2012014127A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
CN102453024B (en) * | 2010-10-27 | 2014-09-03 | 浙江九洲药业股份有限公司 | Nilotinib hydrochloride crystalline form and preparation method thereof |
WO2012070062A2 (en) * | 2010-11-26 | 2012-05-31 | Hetero Research Foundation | Novel polymorph of nilotinib hydrochloride |
AR086913A1 (en) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-METIL-3 - [[4- (3-PIRIDINIL) -2-PIRIMIDINIL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO-METIL) -FENIL] -BENZAMIDA AMORFA, FORM OF DOSAGE THAT CONTAINS AND METHOD TO PREPARE |
WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
AU2012328979B2 (en) | 2011-10-28 | 2016-04-21 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
KR20140093230A (en) | 2011-11-14 | 2014-07-25 | 노파르티스 아게 | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation |
JP2015522070A (en) | 2012-07-11 | 2015-08-03 | ノバルティス アーゲー | How to treat gastrointestinal stromal tumors |
WO2014059518A1 (en) * | 2012-10-15 | 2014-04-24 | Apotex Technologies Inc. | Solid forms of nilotinib hydrochloride |
CA2887540A1 (en) * | 2012-10-19 | 2014-04-24 | Basf Se | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
MX2015014897A (en) | 2013-04-24 | 2016-03-07 | Reddys Lab Ltd Dr | Polymorphic forms of nilotinib hydrochloride. |
RU2551359C9 (en) * | 2013-11-28 | 2021-08-20 | Общество с ограниченной ответственностью "Мамонт Фарм" | Nanosize weakly crystalline modification of 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benazamide hydrochloride monohydrate, method for production thereof and pharmaceutical composition based thereon |
WO2015092624A1 (en) | 2013-12-16 | 2015-06-25 | Ranbaxy Laboratories Limited | Nilotinib mono-oxalate and its crystalline form |
US9926296B2 (en) | 2014-08-08 | 2018-03-27 | Dr. Reddy's Laboratories Limited | Process for the preparation of polymorphic forms of nilotinib hydrochloride |
PL3189045T3 (en) * | 2014-08-11 | 2022-04-04 | Sun Pharmaceutical Industries Limited | Novel salts of nilotinib and polymorphs thereof |
US10301282B2 (en) | 2015-03-20 | 2019-05-28 | Cipla Limited | Polymorphic form X of nilotinib dihydrochloride hydrate |
WO2017129694A1 (en) | 2016-01-26 | 2017-08-03 | Farma Grs, D.O.O. | Nilotinib dinitrate (v) and crystalline forms thereof |
WO2017149550A1 (en) * | 2016-03-02 | 2017-09-08 | Msn Laboratories Private Limited | Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide |
US10640487B2 (en) | 2016-03-14 | 2020-05-05 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of Nilotinib salts |
EP3404025B1 (en) | 2017-05-16 | 2019-12-04 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure nilotinib and its salt |
CZ2017821A3 (en) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Dosing of crystalline nilotinib |
CN113292537B (en) * | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | Salts of kinase inhibitors and compositions thereof |
WO2020095187A1 (en) * | 2018-11-05 | 2020-05-14 | Laurus Labs Limited | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same |
JP7211644B2 (en) * | 2019-02-18 | 2023-01-24 | スレイバック・ファーマ・エルエルシー | Nilotinib pharmaceutical composition |
WO2021155254A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
US20230075170A1 (en) | 2020-02-15 | 2023-03-09 | Cipla Limited | Novel salts of nilotinib and polymorphic forms thereof |
WO2021222739A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
CN114133378B (en) * | 2020-09-04 | 2023-08-15 | 成都苑东生物制药股份有限公司 | Nilotinib hydrochloride eutectic and preparation method thereof |
EP4260848A1 (en) | 2022-04-11 | 2023-10-18 | Lotus Pharmaceutical Co., Ltd. | Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation |
WO2024142002A1 (en) | 2022-12-29 | 2024-07-04 | Renata Pharmaceuticals (Ireland) Limited | Pharmaceutical suspension of nilotinib |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2081108C1 (en) * | 1991-10-16 | 1997-06-10 | Циба-Гейги АГ | Additive salts of acids with the base and pharmaceutical composition showing antitumor activity |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
NZ273617A (en) | 1993-10-01 | 1996-11-26 | Ciba Geigy Ag | N-phenyl-2-pyrimidineamine derivatives pharmaceutical compositions |
CO4940418A1 (en) * | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
CA2393358A1 (en) * | 1999-12-14 | 2001-06-21 | Nippon Shinyaku Co., Ltd. | Heterocycle derivatives and drugs |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB2398565A (en) * | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
AR047530A1 (en) | 2004-02-04 | 2006-01-25 | Novartis Ag | FORMS OF SALT OF 4- (4-METHYLIPIPERAZIN-1-ILMETIL) -N- (4-METHYL-3- (4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) PHENYL) -BENZAMIDA |
SA06270147B1 (en) * | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | Process for the Synthesis Of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine |
GT200600316A (en) * | 2005-07-20 | 2007-04-02 | SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA. | |
GT200600315A (en) * | 2005-07-20 | 2007-03-19 | CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA |
-
2006
- 2006-07-14 GT GT200600316A patent/GT200600316A/en unknown
- 2006-07-18 DK DK06787733.2T patent/DK1910336T3/en active
- 2006-07-18 CA CA2823946A patent/CA2823946C/en active Active
- 2006-07-18 CN CN2011102503529A patent/CN102267981A/en active Pending
- 2006-07-18 EP EP06787733A patent/EP1910336B1/en active Active
- 2006-07-18 MY MYPI20063405A patent/MY149889A/en unknown
- 2006-07-18 US US11/995,898 patent/US8163904B2/en active Active
- 2006-07-18 RU RU2011120363/04A patent/RU2483065C2/en active
- 2006-07-18 ES ES10150322.5T patent/ES2634291T3/en active Active
- 2006-07-18 NZ NZ591142A patent/NZ591142A/en unknown
- 2006-07-18 PT PT06787733T patent/PT1910336E/en unknown
- 2006-07-18 RU RU2008105827/04A patent/RU2434864C2/en active
- 2006-07-18 AT AT06787733T patent/ATE514689T1/en active
- 2006-07-18 RU RU2012143989/04A patent/RU2509767C1/en active
- 2006-07-18 CA CA2615669A patent/CA2615669C/en active Active
- 2006-07-18 KR KR1020087001461A patent/KR20080027855A/en not_active Application Discontinuation
- 2006-07-18 WO PCT/US2006/027878 patent/WO2007015871A1/en active Application Filing
- 2006-07-18 KR KR1020157022022A patent/KR101755137B1/en active IP Right Grant
- 2006-07-18 SI SI200631100T patent/SI1910336T1/en unknown
- 2006-07-18 EP EP10150322.5A patent/EP2186808B1/en active Active
- 2006-07-18 AU AU2006276205A patent/AU2006276205C1/en active Active
- 2006-07-18 KR KR1020147007695A patent/KR20140047737A/en not_active Application Discontinuation
- 2006-07-18 MX MX2008000892A patent/MX2008000892A/en active IP Right Grant
- 2006-07-18 NZ NZ564182A patent/NZ564182A/en unknown
- 2006-07-18 BR BRPI0613605-2A patent/BRPI0613605A2/en not_active Application Discontinuation
- 2006-07-18 PL PL06787733T patent/PL1910336T3/en unknown
- 2006-07-18 JP JP2008522900A patent/JP5129132B2/en active Active
- 2006-07-18 AR ARP060103071A patent/AR057467A1/en unknown
- 2006-07-18 SG SG201102150-8A patent/SG170772A1/en unknown
- 2006-07-19 TW TW095126416A patent/TWI455934B/en active
- 2006-07-20 JO JO2006242A patent/JO2757B1/en active
- 2006-07-20 UY UY29683A patent/UY29683A1/en not_active Application Discontinuation
- 2006-07-20 PE PE2006000874A patent/PE20070241A1/en active IP Right Grant
-
2007
- 2007-11-29 IL IL187787A patent/IL187787A/en active IP Right Grant
-
2008
- 2008-01-09 MA MA30563A patent/MA29686B1/en unknown
- 2008-01-18 EC EC2008008118A patent/ECSP088118A/en unknown
- 2008-01-18 TN TNP2008000028A patent/TNSN08028A1/en unknown
- 2008-02-20 NO NO20080897A patent/NO341313B1/en unknown
- 2008-07-08 HK HK08107504.6A patent/HK1116778A1/xx unknown
-
2010
- 2010-11-12 AU AU2010241419A patent/AU2010241419C1/en active Active
-
2011
- 2011-08-26 CY CY20111100813T patent/CY1111772T1/en unknown
- 2011-09-07 HR HR20110639T patent/HRP20110639T1/en unknown
-
2012
- 2012-03-13 US US13/419,132 patent/US8389537B2/en active Active
-
2013
- 2013-01-15 RU RU2013101749/04A patent/RU2605551C2/en active
- 2013-01-22 US US13/747,052 patent/US8580806B2/en active Active
- 2013-10-11 US US14/051,725 patent/US9163005B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ591142A (en) | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | |
EA200901488A1 (en) | SUBSTITUTED IMIDAZOLOPIRIDAZINES AS LIPIDKINASE INHIBITORS | |
BRPI0519597A2 (en) | (3r, 6r) -3- (2,3-dihydro-1h-inden-2-yl) -2,5-piperazinedione 1,6-substituted derivatives as oxytocin receptor antagonists for the treatment of premature labor, dysmenorrhea and endometriosis | |
BRPI0412347A (en) | 2-Aminophenyl-4-phenylpyridines as kinase inhibitors | |
JO3308B1 (en) | Crystalline Forms of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-YL)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3YL-Pyrimidin-2-Ylamino)-Benzamide | |
MY139689A (en) | Imidazotriazines as protein kinase inhibitors | |
EA200900779A1 (en) | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEKINKINASE INHIBITORS | |
RS54878B1 (en) | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile | |
EA200970402A1 (en) | TRIAZOLOPIRIDAZIN PROTEINKINASE MODULATORS | |
NO20080675L (en) | P38-Map kinase inhibitors and methods for their use | |
EA201200669A1 (en) | PYRIDOPYRIMIDINONE INHIBITORS PI3Kα | |
BRPI0511111A (en) | pyrrol compounds as erk protein kinase inhibitors, their synthesis and intermediates | |
EA201070480A1 (en) | C-FMS KINASE INHIBITORS | |
NO20075624L (en) | Novel histamine H3 receptor ligands and their therapeutic uses | |
EA200800728A1 (en) | POLYMORPHES OF BENZOATIC SALT 2 - [[6 - [(3R) -3-AMINO-1-PIPERIDINYL] -3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1 (2H) -PYRIMIDINYL] METHYL] BENZONITRIL AND METHODS OF THEIR APPLICATION | |
EA200900152A1 (en) | PYRROLOTRIAZINKINASE INHIBITORS | |
RS53599B1 (en) | Pyridone derivatives for modulating stress-activated protein kinase system | |
NO20083427L (en) | Cystotoxic agents comprising novel tomaymycin derivatives and their therapeutic use | |
EA200801291A1 (en) | CARBONYLAMINOPYRROPYRAZOLES AS AN EFFICIENT KINAZ INHIBITORS | |
NO20071843L (en) | Substituted aniline derivatives | |
EA200601686A1 (en) | SUBSTITUTED DERIVATIVES OF MORPHOLINE AND THIOMORFOLINE | |
EA200801199A1 (en) | KINASE INHIBITORS | |
WO2007109783A3 (en) | Substituted pyrimidine kinase inhibitors | |
WO2007047646A3 (en) | Substituted dihydro-isoindolones useful in treating kinase disorders | |
BR122018070508B8 (en) | triazole-substituted arylamide derivatives and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 JUL 2013 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20130124 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 JUL 2016 BY CPA GLOBAL Effective date: 20130405 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2017 BY CPA GLOBAL Effective date: 20160603 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2018 BY CPA GLOBAL Effective date: 20170622 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2019 BY CPA GLOBAL Effective date: 20180622 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2020 BY CPA GLOBAL Effective date: 20190620 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2021 BY CPA GLOBAL Effective date: 20200618 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2022 BY CPA GLOBAL Effective date: 20210617 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2023 BY CPA GLOBAL Effective date: 20220616 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2024 BY CPA GLOBAL Effective date: 20230622 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240620 |